Anti biofilm effect of dihydromyricetin-loaded nanocapsules on urinary catheter infected by Pseudomonas aeruginosa

Dalcin, Ana Júlia Figueiró; Santos, Cayane Genro; Gündel, Samanta da Silva; Roggia, Isabel; Raffin, Renata Platcheck; Ourique, Aline Ferreira; Santos, Roberto C.V.; Gomes, Patrícia

doi:10.1016/j.colsurfb.2017.05.029

Cited by 44 publications

(26 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, a similar experiment was conducted by Dalcin et al. (), where the retention rates of DMY in nano‐encapsulation were only 55% and 14% after stored at room temperature and at 40 ± 2 °C for 90 days, respectively, which might indicate that the stability of DMY was enhanced remarkably by S‐SEDS compared to the conventional carriers. And the remarkable increase of stability possibly benefit by the secondary encapsulation of L‐SEDS in the Aerosil 300 during the solidification process.…”

Section: Resultssupporting

confidence: 52%

“…Liu, Yin, Wang, and Li () reported that the absolute bioavailability of DMY by oral route was only 4.02% in rats. In order to overcome these limitations, several formulation strategies have been attempted including microemulsion (Solanki, Sarkar, & Dhanwani, ), solid lipid nanoparticles (Gaber, Nafee, & Abdallah, ), cyclodextrin inclusion complexes (Lahianiskiba, Barbot, Bounoure, Joudieh, & Skiba, ), solid dispersion pellets (Ruan, Yu, Fu, & Zhu, ), and nanocapsules (Dalcin et al., ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Solid Self‐Emulsifying Delivery System (S‐SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food

Wang

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

The present study was aimed at formulating and evaluating a novel solid self-emulsifying delivery system (S-SEDS) for the application in functional foods of dihydromyricetin (DMY). First, solubility study and pseudo-ternary phase diagram analysis were adopted to optimize the formulation of liquid self-emulsifying delivery system (L-SEDS). And the thermodynamic stable L-SEDS with 5% content of DMY was fabricated and further developed into a solid form via vacuum rotary evaporation with Aerosil 300 as the solid adsorbent. Solid state characterization of the S-SEDS was performed by scanning electron microscopy, Fourier-transform infrared spectroscopy, and X-ray powder diffraction. Furthermore, studies proved that the antioxidant activity and bioaccessibility of DMY were improved after incorporated into S-SEDS formulation compared to pure DMY. The S-SEDS showed good resistance against various storage conditions investigated for 10 weeks.Practical Application: Solid self-emulsifying delivery system (S-SEDS) combined the advantages of liquid self-emulsifying delivery system with those of a solid dosage form to overcome the disadvantages associated with liquid formulations is more convenient for storage and transportation in practical application. Furthermore, the technology of producing S-SEDS is simple and can be realized in industrial production. Hence, S-SEDS could be a promising strategy to overcome the poor water solubility and short biological half-life of dihydromyricetin for further application in functional foods and beverage industry.

show abstract

Section: Resultssupporting

confidence: 52%

Section: Introductionmentioning

confidence: 99%

Solid Self‐Emulsifying Delivery System (S‐SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food

Wang

et al. 2019

Journal of Food Science

View full text Add to dashboard Cite

show abstract

“…3b). Dalcin et al (2017) prepared DMY-loaded nanocapsules by insertion of DMY in polymeric nanoparticles. DMY-loaded nanocapsules not only demonstrated improved physicochemical properties (bioavailability) but also effective antimicrobial and anti-biofilm activity on urinary catheters infected by Pseudomonas aeruginosa.…”

Section: Approaches To Enhance Solubility and Bioavailability Of Dmymentioning

confidence: 99%

“…This is a determinant factor that limited the pharmacological effects and clinical application of DMY. To improve the bioavailability of DMY, researchers have tried to use DMY in new drug delivery systems such as inclusion complexes (Liu, Ma, et al, 2012;Ruan, Yu, Fu, & Zhu, 2005;Yang, Liu, Liu, & Zhang, 2011), nano-encapsule (Dalcin et al, 2017) or microemulsion (Solanki, Sarkar, & Dhanwani, 2012), co-crystals (Wang, Tong, et al, 2016), phospholipid complexes (Liu, Du, Jie, Chen, & Niu., 2009), and acylation (Cao et al, 2017;Guo, Zeng, Lu, & Shu, 2013;Li et al, 2015;Li, Zheng, & Ning., 2005) to provide higher solubility and bioavailability. In addition, the pharmacokinetic characteristics of DMY in animal models and human body are also vital to the evaluation of their in vivo bioavailability efficacy.…”

Section: Introductionmentioning

confidence: 99%

Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability

Liú

Mao

Ding

et al. 2019

Trends in Food Science & Technology

View full text Add to dashboard Cite

Background: Dihydromyricetin (DMY) is an important plant flavonoid, which has received great attention due to its health-benefiting activities, including antioxidant, antimicrobial, anti-inflammatory, anticancer, antidiabetic and neuroprotective activities. DMY capsules have been sold in US as a nutraceutical supplement to prevent alcoholic hangovers. The major disadvantage associated with DMY is its chemical instability and poor bioavailability caused by the combined effects of its low solubility and poor membrane permeability. This limits its practical use in the food and pharmaceutical fields. Scope and approach: The present paper gives an overview of the current methods for the identification and quantification of DMY. Furthermore, recent findings regarding the main biological properties and chemical stability of DMY, the metabolism of DMY as well as different approaches to increase DMY bioavailability in both aqueous and lipid phases are discussed. Key findings and conclusions: Current trends on identification and quantification of DMY have been focused on spectral and chromatographic techniques. Many factors such as heat, pH, metal ions, could affect the chemical stability of DMY. Despite the diverse biological effects of DMY, DMY faces with the problem of poor bioavailability. Utilization of different delivery systems including solid dispersion, nanocapsule, microemuslion, cyclodextrin inclusion complexes, co-crystallization, phospholipid complexes, and chemical or enzymatic acylation has the potential to improve both the solubility and bioavailability. DMY digested in laboratory animals undergoes reduction, dehydroxylation, methylation, glucuronidation, and sulfation. Novel DMY delivery systems and basic pharmacokinetic studies of encapsulated DMY on higher animals and humans might be required in the future.

show abstract

“…The MBC results are shown in The action of the EO was faster as compared to N-EO, which can be associated with the gradual release of EO from the nanocapsules (Dalcin et al, 2017), suggesting a controlled release of antimicrobial compounds. In bacteria treated with N-B (bare nanoparticles), no significant differences were observed in the growth of B. cereus and L. monocytogenes in comparison to the control group.…”

Section: Antibacterial Assaysmentioning

confidence: 94%

Polymeric nanoparticles loaded with Baccharis dracunculifolia DC essential oil: Preparation, characterization, and antibacterial activity in milk

Timbe

Motta

Isaía

et al. 2020

J Food Process Preserv

View full text Add to dashboard Cite

Eudragit RS100 nanoparticles containing Baccharis dracunculifolia DC essential oil (N‐EO) was developed by the nanoprecipitation method. N‐EO presented an average diameter of 151.6 nm, zeta potential (ζ) of +51.7 mV, and encapsulation efficiency of 99.4%. The antibacterial activity of N‐EO and free essential oil (EO) was evaluated in BHI broth against Staphylococcus aureus, Bacillus cereus, Listeria monocytogenes, and Salmonella Enteritidis. No viable cell counts were detected for all strains tested up to 4 hr incubation with EO. The same effect was achieved at 24 hr by the N‐EO, suggesting a controlled release of encapsulated EO. The antimicrobial activity was also tested against L. monocytogenes in milk. Both EO and N‐EO lack antibacterial effect in whole milk, while a delayed lag phase was observed in skimmed milk. The N‐EO caused no significant lysis of erythrocytes suggesting that it can be safe to eukaryotic cells. Practical applications The results of this work suggest that Eudragit nanoparticles can be suitable carriers for essential oils, maintaining their antimicrobial activities. Nanoparticle encapsulation may be useful for food applications by hiding the intense flavor of EO and providing a controlled release of bioactive components. The reduced activity in milk suggests the interaction between the nanostructures and EO with food components, which merits additional studies.

show abstract

Anti biofilm effect of dihydromyricetin-loaded nanocapsules on urinary catheter infected by Pseudomonas aeruginosa

Cited by 44 publications

References 53 publications

Solid Self‐Emulsifying Delivery System (S‐SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food

Solid Self‐Emulsifying Delivery System (S‐SEDS) of Dihydromyricetin: A New Way for Preparing Functional Food

Dihydromyricetin: A review on identification and quantification methods, biological activities, chemical stability, metabolism and approaches to enhance its bioavailability

Polymeric nanoparticles loaded with Baccharis dracunculifolia DC essential oil: Preparation, characterization, and antibacterial activity in milk

Contact Info

Product

Resources

About